Skip to main content

Table 4 Summary of overall best response—efficacy population (N = 21)

From: Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

  Cohort 3
(Bel D1-3)
n = 7 		Cohort 5 + Expansion
(Bel D1-5)
n = 14
Overall best response, n (%)
 CR 4 (57) 10 (71)
 PR 2 (29) 2 (14)
 SD 0 1 (7)
 PD 1 (14) 1 (7)
 Missing 0 0
Objective response rate
 CR, n (%) 4 (57) 10 (71)
  95% CI 18.41–90.10 41.90–91.61
 Objective response (CR + PR), n (%) 6 (86) 12 (86)
  95% CI 42.13–99.64 57.19–98.22
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us

\